Research Article

Development and Validation of Ferroptosis-Related lncRNAs as Prognosis and Diagnosis Biomarkers for Breast Cancer

Zhi-Yong Yao,1 Chaoqun Xing,1,2 Shanshan Cai,1 and Xiao-Liang Xing1

1School of Public Health and Laboratory Medicine, School of Basic Medicine, The First Affiliated Hospital of Hunan University of Medicine, Hunan University of Medicine, Huaihua, 418000 Hunan, China
2School of Nursing, Youjiang Medical College for Nationalities, Baise, 533000 Guangxi, China

Correspondence should be addressed to Xiao-Liang Xing; xiaoliangxinghnm@126.com

Received 12 May 2022; Revised 7 August 2022; Accepted 23 September 2022; Published 18 October 2022

Academic Editor: Simona Saponara

Copyright © 2022 Zhi-Yong Yao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Breast cancer (BC) is one of the most common malignancies affecting women. Ferroptosis is a novel cancer treatment option. The present study is aimed to identify suitable ferroptosis-related lncRNAs to predict and diagnose BC. Differential expression and Cox regression analyses were used to screen suitable prognostic biomarkers and construct a suitable risk model. We identified four ferroptosis-related differentially expressed lncRNAs (FR-DELs) (LINC01152, AC004585.1, MAPT-IT1, and AC026401.3), which were independently correlated with the overall survival of BC patients. The area under the curve value of the prognostic model using those four biomarkers was over 0.60 in all three groups. The sensitivity and specificity of the diagnostic model using those four biomarkers were 86.89% and 86.73%, respectively. Our present study indicated that these four FR-DELs (LINC01152, AC004585.1, MAPT-IT1, and AC026401.3) could be prognostic biomarkers for BC, although clinical validation studies are required.

1. Introduction

With more than 2 million new cases (11.7% of all new cancer cases) and 68 thousand deaths (6.9% of all cancer deaths) in 2020 globally, breast cancer (BC) is one of the most common malignancies in women [1]. With the development of early screening and anticancer strategies, the treatment effect of BC has improved dramatically [2]. However, the recurrence rates of BC remain high [3, 4]. Additionally, evidence has indicated that BC’s prognosis is affected by many factors, such as age, tumor size, grade, lymph node involvement, and lymphatic vascular infiltration [5, 6]. The prognosis of BC remains a complex problem, even though many BC prognostic biomarkers have been discovered in ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up [5–13]. Constructing a new risk assessment model to predict the prognosis of BC patients is necessary.

The main treatments for BC are surgery with adjuvant radiation therapy and chemotherapy [14–18]. However, many BC patients are resistant to chemotherapy, endocrine, and targeted therapy, and these patients generally have poor survival rates [6, 19–24]. The complexity and high heterogeneity of the underlying mechanisms of BC make its treatment difficult [25–29]. Ferroptosis is a novel type of cell death that plays an essential role in the progression of many diseases, including cancers [30]. Intriguingly, previous studies have indicated that erastin, a ferroptosis inducer, could enhance the effectiveness of chemotherapy drugs [31–34]. These results suggest that ferroptosis may be a novel anticancer therapeutic strategy.

Long noncoding RNAs (lncRNA) are a class of transcripts with 200 nucleotides in length, which generally do not have protein-coding potential. Previous evidence demonstrated that lncRNAs play an essential role in various biological processes, including the proliferation, apoptosis, migration, and invasion of cancer cells [35–38]. Many lncRNAs are closely related to the survival status and could be prognostic biomarkers for several cancers [39–41]. Therefore, we aimed to identify suitable ferroptosis-related lncRNAs as prognostic biomarkers to predict the outcome of BC.
(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Figure 1: Continued.
2. Materials and Methods

2.1. Data Acquisition. The RNAseq data (counts) and their corresponding clinical information for 1215 samples (113 normal and 1102 BC patients) were downloaded from the Cancer Genome Atlas database (https://portal.gdc.cancer.gov/projects/TCGA-BRCA). The annotation lncRNAs and recognized ferroptosis-related genes were downloaded from the Gene Transfer Format file [42] and FerrDb [43], respectively. Using the Estimate script in R (3.6.1), we used all normalized gene expression values to evaluate Stromal Score, Immune Score, Tumor Purity, and Estimate Score. The evaluated infiltrating score of immune cells and immune factors were downloaded from Tumor IMMune Estimation Resource (TIMER).

2.2. Differentially Expressed Analyses. DESeq2 in R (3.6.1) was used to screen the differentially expressed genes with the specific criterion as follows: adj. \( p < 0.05 \), \(|\log FC| \geq 0.5\), and baseMean \( \geq 50\). The ferroptosis-related DEGs (FR-DEGs) were obtained by overlapping with the recognized ferroptosis-related genes. The ferroptosis-related lncRNAs (FR-Lncs) were obtained by correlation analyses of FR-DEGs with DELs with the following criteria: \( p < 0.05 \) and \( r > 0.5\).

2.3. Survival Analyses and Principal Component Analyses. After regrouping the samples by the median value of each gene, we performed univariate and multivariate Cox regression analyses using survival, survminer, and regparallel packages in R software (3.6.1). We carry out the principal component analyses (PCA) in R software (3.6.1).

2.4. Construction of Prognostic and Diagnosis Model

(1) Prognostic model, Risk value = Express\(_{LINC01152}\) \( \beta_{AC004585.1} \) + \( \beta_{AC026401.3} \) * Express\(_{AC026401.3}\). The expression values were obtained from the normalized value of DESeq2 analyses, and the constant and \( \beta \) were obtained from a stepwise logistic regression analysis [44].

(2) Diagnosis model, The Logit value = Constant + Express\(_{LINC01152}\) \( \beta_{LINC01152} \) + \( \beta_{AC004585.1} \) * Express\(_{AC004585.1}\) + Express\(_{MAPT-IT1}\) \( \beta_{MAPT-IT1} \) + Express\(_{AC026401.3}\) \( \beta_{AC026401.3} \). The \( \beta \) values were obtained from multivariate Cox regression analyses and the constant and \( \beta \) were obtained from the Youden index (cutoff value = −15.25) in the training group. The Kaplan-Meier curves of those four FR-DEGs were displayed in Figures 1(g)–1(j).

2.5. Statistical Analyses. Unpaired two-tailed Student’s t-test was used to investigate the relationship of risk value with the clinical characteristics. Time-dependent receiver operating characteristic (ROC) curves were used to estimate the utility of the outcome prediction.

3. Results

3.1. Differential Expression Analyses. Through differentially expressed analyses, we obtained 8495 DEGs, including 5337 upregulated DEGs and 3158 downregulated DEGs (Figure 1(a)). By overlapping analyses of DEGs with ferroptosis genes, we obtained 119 FR-DEGs (65 upregulated DEGs and 54 downregulated DEGs) (Figure 1(b)). Through similar analyses, we obtained 709 DELs, including 430 upregulated DELs and 279 downregulated DELs (Figure 1(c)). To obtain FR-DEls, we introduced the Spearman correlation analyses for these 119 FR-DEGs and 709 DELs and obtained 787 pairs of FR-DEGs-DELs, including 74 FR-DEGs and 203 DELs. We named these 203 DELs as FR-DELs.

3.2. Development and Validation of Prognosis Biomarkers. To screen for suitable prognosis biomarkers and verify them, we randomly divided the BC patients into training and validation groups (Table 1). We found that 13 FR-DEls (Figure 1(d)) and four FR-DELs (Figure 1(e)) were correlated with the overall survival (OS) of patients with BC by univariate and multivariate Cox regression analyses, respectively, in the training group. The expression of LINC01152 was significantly decreased, while AC004585.1, MAPT-IT1, and AC026401.3 increased significantly (Figure 1(f)). The Kaplan-Meier curves of those four FR-DEls were displayed in Figures 1(g)–1(j).

We used these four FR-DELs to construct a risk assessment model in the training, validation, and entire group. The Youden index (cutoff value = −15.25) in the training group was used to regroup the patients with BC into low and high-risk groups (Supplementary Figure 1). The risk
value and survival status for each patient in the training group were displayed in Figure 2(a). The expressions of these four FR-DELs were significantly decreased in patients with BC with high-risk values (Figure 2(b)). The BC patients with high-risk values displayed worse OS (Figure 2(c)).

Subsequently, we performed similar analyses in the validation and entire groups. These results were shown in Figures 2(e)–2(l). PCA analyses indicated that these BC patients with high-risk values could well be distinguished from the BC patients with low-risk values using these four FR-DELs (Figures 2(d), 2(h), and 2(l)).

### 3.3. Independent Prognostic Factors of Overall Survival.

To know whether the risk model could be used independently, we performed univariate and multivariate Cox regression analyses for different clinical features and the risk model. We found that age, pathological TNM, pathological Stage, and risk model were correlated with the OS, whereas age, pathological M, and risk model were correlated with the OS independently (Figure 3(a)). In the validation group, the age, pathological NM, pathological Stage, and risk model were correlated with the OS by univariate Cox regression analyses. In contrast, age and pathological M were correlated with the OS by multivariate Cox regression analyses (Figure 3(b)). In the entire group, the age, pathological NM, pathological Stage, and risk model were correlated with the OS by univariate Cox regression analyses, whereas the age, pathological M, pathological Stage, and risk model were correlated with the OS by multivariate Cox regression analyses (Figure 3(c)). Compared with pathological TNM and Stage, these results suggested that these four FR-DELs were more accurate as measured by the ROC analyses (Figure 3(d)–3(f)). The area under curve (AUC) value of the prognostic model using those four biomarkers was over 0.60 in all three groups. Subsequently, we performed ROC curves analyses at 1, 3, 5, and 10-year in the entire group (Figure 3(g)).

### Table 1: Clinical features of BC in different groups.

| Clinical features | Entire (n = 1091) | Training (n = 546) | Validation (n = 545) |
|-------------------|-------------------|-------------------|---------------------|
| Age               |                   |                   |                     |
| ≤65               | 772               | 388               | 384                 |
| >65               | 319               | 158               | 161                 |
| Gender            |                   |                   |                     |
| Female            | 1079              | 539               | 540                 |
| Male              | 12                | 7                 | 5                   |
| Stage             |                   |                   |                     |
| Stage I           | 181               | 87                | 94                  |
| Stage II          | 619               | 312               | 307                 |
| Stage III         | 248               | 133               | 115                 |
| Stage IV          | 20                | 7                 | 13                  |
| Unknown           | 23                | 7                 | 16                  |
| T                 |                   |                   |                     |
| T1                | 279               | 133               | 146                 |
| T2                | 631               | 321               | 310                 |
| T3                | 138               | 71                | 67                  |
| T4                | 40                | 20                | 20                  |
| TX                | 3                 | 1                 | 2                   |
| N                 |                   |                   |                     |
| N0                | 514               | 252               | 262                 |
| N1                | 361               | 187               | 174                 |
| N2                | 120               | 60                | 60                  |
| N3                | 76                | 40                | 36                  |
| Unknown           | 20                | 7                 | 13                  |
| M                 |                   |                   |                     |
| M0                | 908               | 456               | 452                 |
| M1                | 22                | 8                 | 14                  |
| Unknown           | 161               | 82                | 79                  |
| Vital             |                   |                   |                     |
| Alive             | 939               | 482               | 457                 |
| Death             | 152               | 64                | 88                  |
Figure 2: Continued.
To know the relationship of the risk model with clinical features, we performed comparative analyses for risk value in different groups for the entire group. The results were displayed in Figures 4(a)–4(e). Then, we performed comparative analyses for these four FR-DELs in sets for the entire group. The results were shown in Figures 4(f)–4(j). Additionally, we performed the correlation analyses for the risk model with the different clinical features and found no significant correlation (Figure 4(k)).

3.4. Correlation Analyses with the Immunity. Previous studies demonstrated that ferroptosis and the immune system could regulate each other to achieve their antitumor effect. We used the ESTIMATE package to evaluate the immune status. We found that the ESTIMATE score and stromal score were significantly decreased while the immune score and tumor purity were significantly increased in the patients with BC (Supplementary Figures 2(a)–2(d)). In the patients with BC with a high-risk value, the ESTIMATE score, immune scores, and stromal scores were significantly decreased while the tumor purity was significantly increased (Figure 5(a)–5(d)). The correlations of ESTIMATE score, immune score, stromal score, tumor purity, and risk value were displayed in Figures 5(e)–5(f).

We also carried out the difference analyses for the infiltration of immune cells and immune factors of each BC patient. We found that 84 immune cells and factors differ between normal and BC patients. Of the 84, we found that 55 immune cells and factors differ significantly (Figures 6(a)–6(g)). We introduced the correlation analyses for the risk value and these 55 immune cells and factors. We found that four immune cells and factors were significantly correlated with the risk model in the entire group.

3.5. Construction of a Diagnostic Model. X-ray mammography is the golden standard for diagnosing BC patients, which has some drawbacks, such as unsuitability for people under 40, for people with high gland density, can be done no more than twice a year, and high cost [45]. Therefore, to know its role in diagnosing patients with BC, we performed a stepwise logistic regression analysis for these four FR-DELs and constructed a diagnosis model according to previous studies. The sensitivity and specificity of the diagnosis model were 86.89% and 86.73%, respectively (Table 2). We also
Figure 3: Prognostic factors of clinical features for BC. (a-c), univariate (blue) and multivariate (red) Cox regression analyses for clinical features and the risk model in the training (a), validation (b), and entire group (c), respectively. (d-f), comparison of ROC curve of risk model with the clinical features. (d), for patients in the training group. (e), for patients in the validation group. (f), for patients in the entire group. (g), time-dependent ROC curve of the risk model in the entire group.
Figure 4: Continued.
**Figure 4:** Correlation of risk value and prognosis biomarkers with clinical features. (a-e), correlation of risk value with clinical features. (a), for the pathologic Stage. (b), for pathologic T. (c), for pathologic N. (d), for pathologic M. (e), for age. (f-j), correlation of expression of these four FR-DELs with clinical features. (f), for the pathologic Stage. (g), for pathologic T. (h), for pathologic N. (i), for pathologic M. (j), for age. (k), correlation analyses for the risk model with the clinical features. *p < 0.05, **p < 0.01, ***p < 0.001.

**Figure 5:** Comparison and correlation analyses of risk assessment model with the immunity. (a-d), comparison of the ESTIMATE score (a), immune score (b), stromal score (c), and tumor purity (d) between the patients with BC with high- and low-risk values. (e-f), correlation analyses for ESTIMATE score, immune score, stromal score, and tumor purity between the normal and patients with BC patients (e), between patients with BC with high- and low-risk value (f). ***p < 0.001.
Figure 6: Continued.
Figure 6: Correlation analyses of risk value with the immune infiltration. (a-g), differentially expression analyses of infiltrating score between BC patients with low-risk value and BC patients with high-risk value. (a), XCELL. (b), QUANTISEQ. (c), MCPCOUNTER. (d), TIMER. (e), CIBERSORT-ABS. (f), CIBERSORT. (g), EPIC. (h), the immune cells and factors significantly correlated with the risk model. *p < 0.05, **p < 0.01, ***p < 0.001.
In the present study, we found four FR-DELs (LINC01152, AC004585.1, MAPT-IT1, and AC026401.3) correlated with the OS of BC. Previous studies also demonstrated that AC026401.3 was correlated with the OS and could be a prognosis biomarker for several cancers, including renal adenocarcinoma, colon adenocarcinoma, and ovarian cancer. These results indicated that AC026401.3 might play an essential role in developing a variety of cancers.

Although imaging diagnoses have high sensitivity and specificity, these methods also have some major drawbacks, such as being unsuitable for people under 40, for people with high gland density, and can be done no more than twice a year [45]. Although the sensitivity and specificity of this model were lower than those of imaging diagnosis, molecular biotechnology examination can overcome these shortcomings. LncRNA can regulate the cell cycle of tumor cells and various cell signaling pathways of cancer cell proliferation, apoptosis, migration, and invasion of cancer cells [35–38], which could be prognostic and diagnostic biomarkers for several cancers [39–41]. Such as Ye et al. found that the AUC value of myocardial infarction associated transcript as a diagnostic biomarker was 0.86, and the sensitivity and specificity were 87.80% and 75.61%, respectively [51]. El-Ashmawy et al. found that lncRNA-ATB had a high AUC value (AUC: 0.844, p < 0.01) for early diagnosis of breast cancer in patients with stage I-II [52]. In our present study, we found that the AUC value of the diagnostic model reached 0.927. The sensitivity and specificity of this diagnostic model were 86.89% and 86.73%, respectively. These results suggest that this model may be a better diagnostic model for breast cancer, although further studies are needed to verify it. Additionally, although the sensitivity and specificity of this model were lower than those of imaging diagnosis, it can overcome these shortcomings.

### 5. Conclusions
In the present study, we found four FR-DELs (LINC01152, AC004585.1, MAPT-IT1, and AC026401.3) that could be used as prognosis and diagnosis biomarkers to predict the outcome of BC. Our study provides a new perspective on the prognosis and diagnosis of BC, although there were several limitations, especially due to the lack of clinical validation.

### Data Availability
The data that support the findings of this study are openly available in TCGA at https://portal.gdc.cancer.gov/.

### Conflicts of Interest
The authors declare no competing interests.

### Authors’ Contributions
Zhi-Yong Yao and Chaoqun Xing contributed equally to this work.
Acknowledgments

This project is financially supported by Doctor Foundation of Hunan University of Medicine (2020212004), Hunan Provincial Science and Technology Department (2021SK4004).

Supplementary Materials

Supplementary Figure 1: youden index from the training group. Supplementary Figure 2: comparison analyses of risk assessment model of the ESTIMATE score between normal and cancer. Supplementary Figure 3: ROC curve of the diagnosis model. (Supplementary Materials)

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] Y. Kim, H. Cho, N. Lee et al., “Doxorubicin-induced heart failure in cancer patients: a cohort study based on the Korean national health insurance database,” Cancer Medicine, vol. 7, no. 12, pp. 6084–6092, 2018.
[3] B. Yang, J. Chou, Y. Tao et al., “An assessment of prognostic immunity markers in breast cancer,” NPJ Breast Cancer, vol. 4, no. 1, p. 35, 2018.
[4] R. N. Pedersen, B. O. Esen, L. Mellemkjær et al., “The incidence of breast cancer recurrence 10-32 years after primary diagnosis,” Journal of the National Cancer Institute, vol. 114, no. 3, pp. 391–399, 2022.
[5] E. Senkus, S. Kyriakides, S. Ohno et al., “Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 26, Suppl 5, pp. v8–30, 2015.
[6] F. Cardoso, S. Kyriakides, S. Ohno et al., “Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 30, no. 8, pp. 1194–1220, 2019.
[7] W. Lou, J. Liu, B. Ding, L. Xu, and W. Fan, “Identification of chemoresistance-associated miRNAs in breast cancer,” Cancer Management and Research, vol. 10, pp. 4747–4757, 2018.
[8] T. Tian, M. Wang, Y. Zhu et al., “Expression, clinical significance, and functional prediction of _MNX1_ in breast cancer,” Mol Ther Nucleic Acids, vol. 13, pp. 399–406, 2018.
[9] A. Nicolini, P. Ferrari, and M. J. Duffy, “Prognostic and predictive biomarkers in breast cancer: past, present and future,” Seminars in Cancer Biology, vol. 52, Part 1, pp. 56–73, 2018.
[10] Y. Xiao, Z. Deng, Y. Li et al., “ANLN and UBE2T are prognostic biomarkers associated with immune regulation in breast cancer: a bioinformatics analysis,” Cancer Cell International, vol. 22, no. 1, p. 193, 2022.
[11] L. Yi, Y. Lei, F. Yuan, C. Tian, J. Chai, and M. Gu, “NTN4 as a prognostic marker and a hallmark for immune infiltration in breast cancer,” Scientific Reports, vol. 12, no. 1, p. 10567, 2022.
[12] M. Deng, C. Xiong, Z. K. He et al., “MCTS1 as a novel prognostic biomarker and its correlation with immune infiltrates in breast cancer,” Frontiers in Genetics, vol. 13, article 825901, 2022.
[13] T. Wei, N. Zhu, W. Jiang, and X. L. Xing, “Development and validation of ferroptosis- and immune-related lncRNAs signatures for breast infiltrating duct and lobular carcinoma,” Frontiers in Oncology, vol. 12, article 844642, 2022.
[14] J. A. Bradley and N. P. Mendenhall, “Novel radiotherapy techniques for breast cancer,” Annual Review of Medicine, vol. 69, no. 1, pp. 277–288, 2018.
[15] E. K. Oikononmou, D. G. Kokkinidis, P. N. Kampakis et al., “Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis,” JAMA Cardiology, vol. 4, no. 10, pp. 1007–1018, 2019.
[16] A. N. J. Tutt, J. E. Garber, B. Kaufman et al., “Adjuvant olaparib for patients withBRCA1- or BRCA2-Mutated breast cancer,” The New England Journal of Medicine, vol. 384, no. 25, pp. 2394–2405, 2021.
[17] S. A. Valente and C. Shah, “The landmark series: adjuvant radiation therapy for breast cancer,” Annals of Surgical Oncology, vol. 27, no. 7, pp. 2203–2211, 2020.
[18] R. A. Freedman, S. L. Graff, M. R. Somerfield, M. L. Telli, A. C. Wolff, and S. H. Giordano, “Adjuvant abemaciclib plus endocrine therapy in the treatment of high-risk early breast cancer: ASCO guideline rapid recommendation update q and a,” JCO Oncol Pract, vol. 18, no. 7, pp. 516–519, 2022.
[19] Y. Wang, B. Song, L. Zhu, and X. Zhang, “Long non-coding RNA, LINC01614 as a potential biomarker for prognostic prediction in breast cancer,” PeerJ, vol. 7, article e7976, 2019.
[20] J. Huang, J. Li, J. Tang et al., “ZDHHC22-mediated mTOR palmitoylation restrains breast cancer growth and endocrine therapy resistance,” International Journal of Biological Sciences, vol. 18, no. 7, pp. 2833–2850, 2022.
[21] M. Niu, M. Shan, Y. Liu et al., “DCTPP1, an oncogene regulated by miR-378a-3p, promotes proliferation of breast cancer via DNA repair signaling pathway,” Frontiers in Oncology, vol. 11, article 641931, 2021.
[22] P. Ferrari, C. Scatena, M. Ghilli, I. Bargagna, G. Lorenzini, and A. Nicolini, “Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC,” International Journal of Molecular Sciences, vol. 23, no. 3, p. 1665, 2022.
[23] F. Cardoso, S. Paluch-Shimon, E. Senkus et al., “5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC5),” Annals of Oncology, vol. 31, no. 12, pp. 1623–1649, 2020.
[24] S. Paluch-Shimon, F. Cardoso, A. H. Partridge et al., “ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4),” Annals of Oncology, vol. 31, no. 6, pp. 674–696, 2020.
[25] Y. Liang, H. Zhang, X. Song, and Q. Yang, “Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets,” Seminars in Cancer Biology, vol. 60, pp. 14–27, 2020.
[26] S. Cocco, A. Leone, M. Piezzo et al., “Targeting autophagy in breast cancer,” International Journal of Molecular Sciences, vol. 21, no. 21, p. 7836, 2020.
[27] N. Gandhi and G. M. Das, “Metabolic reprogramming in breast cancer and its therapeutic implications,” Cell, vol. 8, no. 2, 2019.
[28] L. Jin, B. Han, E. Siegel, Y. Cui, A. Giuliano, and X. Cui, “Breast cancer lung metastasis: molecular biology and
therapeutic implications," Cancer Biology & Therapy, vol. 19, no. 10, pp. 858–868, 2018.

[29] M. Hosonaga, H. Saya, and Y. Arima, "Molecular and cellular mechanisms underlying brain metastasis of breast cancer," Cancer Metastasis Reviews, vol. 39, no. 3, pp. 711–720, 2020.

[30] J. Li, F. Cao, H. L. Yin et al., "Ferroptosis: past, present and future," Cell Death & Disease, vol. 11, no. 2, p. 88, 2020.

[31] Y. Yang, T. Liu, C. Hu et al., "Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration-resistant prostate cancer," Oncology Reports, vol. 45, no. 4, 2021.

[32] Y. Zhao, X. Li, R. Zhang, F. Wang, T. Wang, and Y. Jiao, "The role of erastin in ferroptosis and its prospects in cancer therapy," Oncotargets and Therapy, vol. 13, pp. 5429–5441, 2020.

[33] Y. Shibata, H. Yasui, K. Higashikawa, N. Miyamoto, and Y. Kuge, "Erastin, a ferroptosis-inducing agent, sensitizes cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo," PLoS One, vol. 14, no. 12, article e0225931, 2019.

[34] C. Gai, C. Liu, X. Wu et al., "MT1DP, loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells," Cell Death & Disease, vol. 11, no. 9, p. 751, 2020.

[35] Y. Liang, X. Song, Y. Li et al., "LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis," Molecular Cancer, vol. 19, no. 1, p. 85, 2020.

[36] T. P. Tang, C. X. Qin, and H. Yu, "MCM3AP-AS1 regulates proliferation, apoptosis, migration, and invasion of breast cancer cells via binding with ZFP36," Translational Cancer Research, vol. 10, no. 10, pp. 4478–4488, 2021.

[37] Z. Li, X. Qin, W. Bian et al., "Exosomal IncRNA ZFAS1 regulates esophageal squamous cell carcinoma cell proliferation, invasion, migration and apoptosis via microRNA-124/STAT3 axis," Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 477, 2019.

[38] A. Bhan, M. Soleimani, and S. S. Mandal, "Long noncoding RNA and cancer: a new paradigm," Cancer Research, vol. 77, no. 15, pp. 3965–3981, 2017.

[39] C. N. Fan, L. Ma, and N. Liu, "Systematic analysis of IncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer," Journal of Translational Medicine, vol. 16, no. 1, p. 264, 2018.

[40] G. Zhang, N. Chi, Q. Lu, D. Zhu, and Y. Zhuang, "LncRNA PTCS3C is a biomarker for the treatment and prognosis of gastric cancer," Cancer Biotherapy & Radiopharmaceuticals, vol. 35, no. 1, pp. 77–81, 2020.

[41] D. Zhang, D. Du, S. Yi, and X. Li, "LncRNA PCAT6: a potential biomarker for diagnosis and prognosis of bladder cancer," Annals of Diagnostic Pathology, vol. 49, article 151642, 2020.

[42] A. Frankish, M. Diekhans, I. Jungreis et al., "Gencode 2021," Nucleic Acids Research, vol. 49, no. D1, pp. D916–D923, 2021.

[43] N. Zhou and J. Bao, "FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations," Database: The Journal of Biological Databases and Curation, vol. 2020, 2020.

[44] X. L. Xing, Y. Liu, J. Liu et al., "Comprehensive analysis of ferroptosis- and immune-related signatures to improve the prognosis and diagnosis of kidney renal clear cell carcinoma," Frontiers in Immunology, vol. 13, article 851312, 2022.